On February 11, 2011, Shanghai Pharmaceutical (601607.SH) announced that recently, the amiodarone hydrochloride injection (hereinafter referred to as "the drug") of Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. ("Xinyi Jinzhu"), a wholly-owned subsidiary of Shanghai Pharmaceutical Group Co., Ltd., received the "Drug Registration Certificate" (certificate number: 2022S00028) issued by the State Drug Administration, and the drug was approved for production.
Amiodarone hydrochloride injection is mainly used to treat severe arrhythmias. It was first developed by Sanofi and launched in France in 1976. In January 2019, Xinyi Jinzhu submitted an application for registration and listing to the State Food and Drug Administration for the drug, which was accepted. As of the announcement date, the company has invested about RMB3.9365 million in research and development expenses for the drug.
As of the announcement date, the main manufacturers of the drug in China are Shandong Dongfangming Pharmaceutical Group Co., Ltd. and Zhuhai Rundu Pharmaceutical Co., Ltd.
According to the IQVIA database, the market size of amiodarone hydrochloride injection in 2021 is RMB194 million.
This article originated from Grand Gateway
![He is strong, he is strong, and he fights for his mother[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)